Through this application M. D. Anderson Cancer Center seeks funding for a new Prostate Cancer SPORE. Under the leadership of Dr. Christopher J. Logothetis, Principal Investigator, and Dr. Timothy C. Thompson, Co-Principal Investigator, who are recognized internationally for their research in prostate cancer, the M. D. Anderson Cancer Center Prostate SPORE has created a stable and dynamic infrastructure for translational research that works toward the development of non-morbid therapies for patients with localized prostate cancer;the identification of predictive biomarkers for therapeutic response;the development of new biologically targeted therapeutic agents;and the linkage of epidemiological and molecular signaling profiles for virulent prostate cancer. We continue to build on our capacity to conduct novel and innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal we define our translational research objectives as (1) development of quantitative tools for determination of aggressive prostate cancers;(2) testing of novel therapeutic agents in proof of principle clinical trials;(3) development of predictive biomarkers for identification of patients who will respond to targeted therapies;and (4) development of rational strategies for combination therapies. We will achieve these translational research objectives by identifying and testing obesity-related biomarkers for virulent prostate cancer, clinical testing of GLIPR1-ATM protein and a novel ligand-directed pro-apoptotic peptide (BMTP-11) for prostate cancer, and conducting two hypothesis-driven clinical trials with a novel FGF signaling inhibitor (TKl 258), and combination Src inhibitor (Dasatinib)+Docetaxel in patients with advanced prostate cancer. We will accomplish our goals through 5 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Specimen), a dynamic Developmental Research Program and an effective Career Development Program. We are optimistic that our research efforts will contribute to reductions in the incidence of, and morbidity and mortality from, this devastating disease by translating basic research into clinical practice.

Public Health Relevance

New and effective therapies for prostate cancer are desperately needed. To address this need, the M.D. Anderson Cancer Center Prostate SPORE will build on its capacity to conduct novel and innovative clinical trials through the execution of translational research projects that will test novel therapeutic agents in proof-of-principle clinical trials and develop quantitative tools and predictive biomarkers for single and combination targeted therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Other Domestic Higher Education
United States
Zip Code
Jin, J-K; Tien, P-C; Cheng, C-J et al. (2015) Talin1 phosphorylation activates ?1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene 34:1811-21
Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7
Yu, Guoyu; Lee, Yu-Chen; Cheng, Chien-Jui et al. (2015) RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res 13:348-57
Al Olama, Ali Amin; Kote-Jarai, Zsofia; Berndt, Sonja I et al. (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46:1103-9
Satcher, Robert L; Pan, Tianhong; Cheng, Chien-Jui et al. (2014) Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One 9:e89880
Jiang, Xianhan; Li, Xun; Huang, Hai et al. (2014) Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer. Cancer 120:1228-36
Tien, Jean Ching-Yi; Liao, Lan; Liu, Yonghong et al. (2014) The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate. Int J Biol Sci 10:1116-27
Li, Likun; Chang, Wenjun; Yang, Guang et al. (2014) Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7:ra47
Li, Hongge; Tao, Chenqi; Cai, Zhigang et al. (2014) Frs2* and Shp2 signal independently of Gab to mediate FGF signaling in lens development. J Cell Sci 127:571-82
Lin, Zhuo-Yuan; Huang, Ya-Qiang; Zhang, Yan-Qiong et al. (2014) MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer 135:541-50

Showing the most recent 10 out of 77 publications